Yong Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yong Zhou has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Liang Du
Chinese Evidence-Based Medicine/Cochrane Center, Chengdu 610041, China
17 shared publicationsWen Zhuang
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
15 shared publicationsNi Li
Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China
12 shared publicationsRui Zhao
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China
12 shared publicationsXiaoting Wu
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
11 shared publicationsLin Xia
Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, China
9 shared publications
Latest Publications
- 30 September 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 930
Overweight and Obesity-Associated Gastric Cancer Among Non-Asians
- 30 September 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 930
Overweight and Obesity-Associated Gastric Cancer Among Non-Asians
- Open Access
- 29 July 2024
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 9 (1) , 1-3
Hypoxia-induced nuclear localization of ubiquinol-cytochrome-c reductase complex assembly factor 3 (UQCC3) in hepatocellular carcinoma
- 29 July 2024
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 9 (1) , 1-3
Open AccessHypoxia-induced nuclear localization of ubiquinol-cytochrome-c reductase complex assembly factor 3 (UQCC3) in hepatocellular carcinoma
- 6 September 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (37) , 43359-43373
Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer
Antibody drug conjugates (ADCs) have shown promise to be the mainstream chemotherapeutics for advanced HER2-positive cancers, yet the issues of poor drug delivery efficiency, limited chemotherapeutic effects, severe immune responses, and drug resistance remain to be addressed before the clinical applications of ADCs. The DNA aptamer-guided drug conjugates (ApDCs) are receiving growing attention for specific tumors due to their excellent tumor affinity and low cost. Therefore, developing a multivalent ApDC nanomedicine by combining anti-HER2 aptamer (HApt), tetrahedral framework nucleic acid (tFNA), and deruxtecan (Dxd) together to form HApt-tFNA@Dxd might help to address these concerns. In this study, the HER2-targeted DNA aptamer modified DNA tetrahedron (HApt-tFNA) was employed as a system for drug delivery, and the adoption of tFNA could effectively enlarge the drug-loading rate compared to aptamer-guided ApDCs previously reported. Compared with free Dxd and tFNA@Dxd, HApt-tFNA@Dxd showed better structural stability, excellent targeted cytotoxicity to HER2-positive gastric cancer, and increased tissue aggregation ability in tumors. These features and superiorities make HApt-tFNA@Dxd a promising chemotherapeutic medicine for HER2-positive tumors. Our work developed a new targeting nanomedicine by combining DNA nanomaterials and chemotherapeutic agents, which represents a critical advance toward developing novel DNA-based nanomaterials and promoting their potential applications for HER2-positive cancer therapy.
- 6 September 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (37) , 43359-43373
Self-Assembled Multivalent Aptamer Drug Conjugates: Enhanced Targeting and Cytotoxicity for HER2-Positive Gastric Cancer
Antibody drug conjugates (ADCs) have shown promise to be the mainstream chemotherapeutics for advanced HER2-positive cancers, yet the issues of poor drug delivery efficiency, limited chemotherapeutic effects, severe immune responses, and drug resistance remain to be addressed before the clinical applications of ADCs. The DNA aptamer-guided drug conjugates (ApDCs) are receiving growing attention for specific tumors due to their excellent tumor affinity and low cost. Therefore, developing a multivalent ApDC nanomedicine by combining anti-HER2 aptamer (HApt), tetrahedral framework nucleic acid (tFNA), and deruxtecan (Dxd) together to form HApt-tFNA@Dxd might help to address these concerns. In this study, the HER2-targeted DNA aptamer modified DNA tetrahedron (HApt-tFNA) was employed as a system for drug delivery, and the adoption of tFNA could effectively enlarge the drug-loading rate compared to aptamer-guided ApDCs previously reported. Compared with free Dxd and tFNA@Dxd, HApt-tFNA@Dxd showed better structural stability, excellent targeted cytotoxicity to HER2-positive gastric cancer, and increased tissue aggregation ability in tumors. These features and superiorities make HApt-tFNA@Dxd a promising chemotherapeutic medicine for HER2-positive tumors. Our work developed a new targeting nanomedicine by combining DNA nanomaterials and chemotherapeutic agents, which represents a critical advance toward developing novel DNA-based nanomaterials and promoting their potential applications for HER2-positive cancer therapy.
- Open Access
- 15 March 2023
- Published by Wolters Kluwer Health in journal of nutritional oncology
- Vol. 8 (1) , 16-24
Impact of citrus fruit and hesperidin intake on multiple health outcomes: An umbrella review
Citrus fruits are rich sources of several biologically active flavonoids such as hesperidin, naringin, and polymethoxylated flavones. We evaluated the evidence of associations between citrus fruit or hesperidin intake and multiple health outcomes. An umbrella review was conducted for studies performed in humans. Overall, 246 articles were initially identified by searching in 4 databases. Twenty-two meta-analyses and systematic reviews with 28 health outcomes met the inclusion criteria. Citrus fruit intake had beneficial effects on all-cause mortality (relative risk [RR]. 0.90; 95% confidence interval [95% CI], 0.86 to 0.94), cardiovascular diseases (RR, 0.78; 95% CI, 0.66 to 0.92), coronary heart disease (RR, 0.91; 95% CI, 0.86 to 0.96), stroke (RR, 0.74; 95% CI, 0.65 to 0.84), type 2 diabetes mellitus (RR, 0.85; 95% CI, 0.78 to 0.92), and several cancers. Dose-response analyses indicated that each 100-g/d increase in citrus fruit intake could reduce the risks of all-cause mortality by 6% (RR, 0.94; 95% CI, 0.88 to 1.00), stroke by 22% (RR, 0.78; 95% CI, 0.69 to 0.90), and cardia gastric cancer by 40% (RR, 0.60; 95% CI, 0.44 to 0.83). Citrus fruit intake also had beneficial effects on the lipid profile and body weight control (weighted mean difference, −1.28; 95% CI, −1.82 to −0.74). Grapefruits could reduce the systolic blood pressure (weighted mean difference, −2.43, 95% CI, −4.77 to −0.09). Hesperidin supplementation significantly improved inflammation. Citrus fruit intake was generally safe and beneficial for multiple health outcomes in humans. However, grapefruit and pomelo juice may affect the bioavailability of various medications, so care should be exercised before increasing the intake of these fruits or their juices.
- 15 March 2023
- Published by Wolters Kluwer Health in journal of nutritional oncology
- Vol. 8 (1) , 16-24
Open AccessImpact of citrus fruit and hesperidin intake on multiple health outcomes: An umbrella review
Citrus fruits are rich sources of several biologically active flavonoids such as hesperidin, naringin, and polymethoxylated flavones. We evaluated the evidence of associations between citrus fruit or hesperidin intake and multiple health outcomes. An umbrella review was conducted for studies performed in humans. Overall, 246 articles were initially identified by searching in 4 databases. Twenty-two meta-analyses and systematic reviews with 28 health outcomes met the inclusion criteria. Citrus fruit intake had beneficial effects on all-cause mortality (relative risk [RR]. 0.90; 95% confidence interval [95% CI], 0.86 to 0.94), cardiovascular diseases (RR, 0.78; 95% CI, 0.66 to 0.92), coronary heart disease (RR, 0.91; 95% CI, 0.86 to 0.96), stroke (RR, 0.74; 95% CI, 0.65 to 0.84), type 2 diabetes mellitus (RR, 0.85; 95% CI, 0.78 to 0.92), and several cancers. Dose-response analyses indicated that each 100-g/d increase in citrus fruit intake could reduce the risks of all-cause mortality by 6% (RR, 0.94; 95% CI, 0.88 to 1.00), stroke by 22% (RR, 0.78; 95% CI, 0.69 to 0.90), and cardia gastric cancer by 40% (RR, 0.60; 95% CI, 0.44 to 0.83). Citrus fruit intake also had beneficial effects on the lipid profile and body weight control (weighted mean difference, −1.28; 95% CI, −1.82 to −0.74). Grapefruits could reduce the systolic blood pressure (weighted mean difference, −2.43, 95% CI, −4.77 to −0.09). Hesperidin supplementation significantly improved inflammation. Citrus fruit intake was generally safe and beneficial for multiple health outcomes in humans. However, grapefruit and pomelo juice may affect the bioavailability of various medications, so care should be exercised before increasing the intake of these fruits or their juices.
- Open Access
- 22 December 2022
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 130 (3) , 484-494
Red/processed meat consumption and non-cancer-related outcomes in humans: umbrella review
The associations of red/processed meat consumption and cancer-related health outcomes have been well discussed. The umbrella review aimed to summarise the associations of red/processed meat consumption and various non-cancer-related outcomes in humans. We systematically searched the systematic reviews and meta-analyses of associations between red/processed meat intake and health outcomes from PubMed, Embase, Web of Science and the Cochrane Library databases. The umbrella review has been registered in PROSPERO (CRD 42021218568). A total of 40 meta-analyses were included. High consumption of red meat, particularly processed meat, was associated with a higher risk of all-cause mortality, CVD and metabolic outcomes. Dose–response analysis revealed that an additional 100 g/d red meat intake was positively associated with a 17 % increased risk of type 2 diabetes mellitus (T2DM), 15 % increased risk of CHD, 14 % of hypertension and 12 % of stroke. The highest dose–response/50 g increase in processed meat consumption at 95 % confident levels was 1·37, 95 % CI (1·22, 1·55) for T2DM, 1·27, 95 % CI (1·09, 1·49) for CHD, 1·17, 95 % CI (1·02, 1·34) for stroke, 1·15, 95 % CI (1·11, 1·19) for all-cause mortality and 1·08, 95 % CI (1·02, 1·14) for heart failure. In addition, red/processed meat intake was associated with several other health-related outcomes. Red and processed meat consumption seems to be more harmful than beneficial to human health in this umbrella review. It is necessary to take the impacts of red/processed meat consumption on non-cancer-related outcomes into consideration when developing new dietary guidelines, which will be of great public health importance. However, more additional randomised controlled trials are warranted to clarify the causality.
- 22 December 2022
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 130 (3) , 484-494
Open AccessRed/processed meat consumption and non-cancer-related outcomes in humans: umbrella review
The associations of red/processed meat consumption and cancer-related health outcomes have been well discussed. The umbrella review aimed to summarise the associations of red/processed meat consumption and various non-cancer-related outcomes in humans. We systematically searched the systematic reviews and meta-analyses of associations between red/processed meat intake and health outcomes from PubMed, Embase, Web of Science and the Cochrane Library databases. The umbrella review has been registered in PROSPERO (CRD 42021218568). A total of 40 meta-analyses were included. High consumption of red meat, particularly processed meat, was associated with a higher risk of all-cause mortality, CVD and metabolic outcomes. Dose–response analysis revealed that an additional 100 g/d red meat intake was positively associated with a 17 % increased risk of type 2 diabetes mellitus (T2DM), 15 % increased risk of CHD, 14 % of hypertension and 12 % of stroke. The highest dose–response/50 g increase in processed meat consumption at 95 % confident levels was 1·37, 95 % CI (1·22, 1·55) for T2DM, 1·27, 95 % CI (1·09, 1·49) for CHD, 1·17, 95 % CI (1·02, 1·34) for stroke, 1·15, 95 % CI (1·11, 1·19) for all-cause mortality and 1·08, 95 % CI (1·02, 1·14) for heart failure. In addition, red/processed meat intake was associated with several other health-related outcomes. Red and processed meat consumption seems to be more harmful than beneficial to human health in this umbrella review. It is necessary to take the impacts of red/processed meat consumption on non-cancer-related outcomes into consideration when developing new dietary guidelines, which will be of great public health importance. However, more additional randomised controlled trials are warranted to clarify the causality.
- Open Access
Relation of gut microbiota and postoperative gastrointestinal dysfunction in older patients with colon cancer undergoing elective colon resection: a protocol for a prospective, observational cohort study
Introduction Gut microbiota (GM) appears critical for gastrointestinal symptoms, but whether alterations in GM are associated with increased risk of postoperative gastrointestinal dysfunction (POGID) in older patients with colon cancer (CC) undergoing elective colon resection remains unclear. Methods and analysis This study aims to prospectively recruit 284 elderly patients with CC undergoing elective colon resection. GM of fresh faeces specimens is characterised using 16S rRNA gene sequencing. Data are collected preoperatively, daily postoperatively during the in-hospital stay, and follow-up visits are scheduled four times within 30 days after discharge. Associations with POGID will be investigated using logistic regression models to calculate ORs with 95% CIs. The models include the adjustment for age, sex, frequency of spicy diet, coffee drinking and tea drinking, tobacco and alcohol history, diabetes, obesity, gastroenteritis, preoperative gut microbial composition. Furthermore, we will use joint modelling for longitudinal data to study several outcome variables simultaneously. Ethics and dissemination This study was approved by the Institutional Review Board of West China Hospital, Sichuan University (IRB Number: 20201334). The results will be disseminated through peer-reviewed publications or conference presentations. Trial registration number It has been registered in PROSPERO, number CRD42019145032. It has been registered in the Chinese clinical trial registry, number ChiCTR2100043646.
Open AccessRelation of gut microbiota and postoperative gastrointestinal dysfunction in older patients with colon cancer undergoing elective colon resection: a protocol for a prospective, observational cohort study
Introduction Gut microbiota (GM) appears critical for gastrointestinal symptoms, but whether alterations in GM are associated with increased risk of postoperative gastrointestinal dysfunction (POGID) in older patients with colon cancer (CC) undergoing elective colon resection remains unclear. Methods and analysis This study aims to prospectively recruit 284 elderly patients with CC undergoing elective colon resection. GM of fresh faeces specimens is characterised using 16S rRNA gene sequencing. Data are collected preoperatively, daily postoperatively during the in-hospital stay, and follow-up visits are scheduled four times within 30 days after discharge. Associations with POGID will be investigated using logistic regression models to calculate ORs with 95% CIs. The models include the adjustment for age, sex, frequency of spicy diet, coffee drinking and tea drinking, tobacco and alcohol history, diabetes, obesity, gastroenteritis, preoperative gut microbial composition. Furthermore, we will use joint modelling for longitudinal data to study several outcome variables simultaneously. Ethics and dissemination This study was approved by the Institutional Review Board of West China Hospital, Sichuan University (IRB Number: 20201334). The results will be disseminated through peer-reviewed publications or conference presentations. Trial registration number It has been registered in PROSPERO, number CRD42019145032. It has been registered in the Chinese clinical trial registry, number ChiCTR2100043646.
- 1 September 2022
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 117 (9) , 1539
Correlation of Ethnicities and Prevalence of Histological Barrett's Esophagus
An abstract is unavailable. This article is available as a PDF only.
- 1 September 2022
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 117 (9) , 1539
Correlation of Ethnicities and Prevalence of Histological Barrett's Esophagus
An abstract is unavailable. This article is available as a PDF only.
- 1 September 2022
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 117 (9) , 1539
Correlation of Autoimmune Pancreatitis and Risk of Gastric Cancer in East Asian Population
An abstract is unavailable. This article is available as a PDF only.
- 1 September 2022
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 117 (9) , 1539
Correlation of Autoimmune Pancreatitis and Risk of Gastric Cancer in East Asian Population
An abstract is unavailable. This article is available as a PDF only.
- 1 July 2022
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 117 (7) , 1171-1172
Proton Pump Inhibitors and Risk of Mortality: Longer and More Dangerous?
- 1 July 2022
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 117 (7) , 1171-1172
Proton Pump Inhibitors and Risk of Mortality: Longer and More Dangerous?
- 1 May 2022
- Published by Elsevier in Food Chemistry
- Vol. 375, 131816
Cruciferous vegetable and isothiocyanate intake and multiple health outcomes
- 1 May 2022
- Published by Elsevier in Food Chemistry
- Vol. 375, 131816
Cruciferous vegetable and isothiocyanate intake and multiple health outcomes